South Korea Secures Preferential Tariffs Under Trump Administration Trade Agreements

One year after President Trump's "Liberation Day" tariff announcements, South Korea finds itself navigating a complex trade landscape with significant implications for its economy and exports to the United States. According to a logistics update from April 4, 2026, South Korea is among the countries that have negotiated preferential tariff rates with the Trump administration. The country secured a 15 percent tariff rate on pharmaceutical imports, placing it in the same category as Japan, the European Union, and Switzerland. This represents a substantial discount compared to the baseline 100 percent tariff imposed on patented drugs from countries without such agreements, effective July 31, 2026 for large corporations. For steel, aluminum, and copper products, South Korea also benefits from the administration's tiered approach. Under the revised Section 232 measures effective April 6, 2026, while a baseline 25 percent tariff applies to these metals and derivative products, South Korean manufacturers can access a reduced 10 percent rate if they use exclusively U.S.-made steel, aluminum, and copper in their products. The broader context reveals that South Korea, along with other major trading partners, has been actively restructuring its supply chains in response to Trump's tariff regime. Global trade data shows that U.S.-China trade has declined sharply, with supply chains shifting toward countries including Vietnam and Mexico. Simultaneously, allies like South Korea are diversifying their trade partnerships to mitigate tariff impacts. According to economic reports from April 4, 2026, South Korea is among more than twenty trading partners that have yielded to the president's tariff threats and agreed to open their markets to U.S. products. This diplomatic engagement appears to have secured preferential treatment compared to countries lacking such agreements. The pharmaceutical sector presents particular opportunities and challenges for South Korean companies. Those that conclude onshore production agreements combined with Most Favored Nation drug pricing agreements can achieve zero percent tariffs until January 20, 2029, incentivizing investment in U.S. manufacturing. Listeners should note that the Trump administration's tariff landscape continues to evolve. In February 2026, the Supreme Court ruled most emergency tariffs unconstitutional, forcing the administration to implement new measures. The current framework under Section 232 and Trade Act provisions appears more durable, directly affecting South Korean exporters across multiple sectors. For South Korean businesses and listeners tracking these developments, staying informed about tariff classification changes and negotiated rates remains essential as the administration rolls out new guidance on reporting requirements and tariff calculations. Thank you for tuning in to South Korea Tariff News and Tracker. Please subscribe for the latest updates on trade policy and its impact on the Kore This content was created in partnership and with the help of Artificial Intelligence AI.